Refractory B-Cell Lymphoma Clinical Trial
Official title:
An Observational Clinical Study on the Safety and Efficacy of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19/CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06158386 -
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
|
Phase 2 | |
Recruiting |
NCT05003141 -
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04300998 -
Study of CAR-T Therapy in Older Patients
|
||
Not yet recruiting |
NCT03690310 -
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
|
Early Phase 1 | |
Not yet recruiting |
NCT03692767 -
Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
|
Early Phase 1 | |
Recruiting |
NCT06378190 -
Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03824951 -
Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
|
Early Phase 1 |